Erythropoietin protects podocytes from damage by advanced glycation end-products

Nephron - Experimental Nephrology

Volumn 117, Issue 1, 2010, Pages

  Ruester, Christiane ^a   Franke, Sybille ^a   Bondeva, Tzvetanka ^a   Wolf, Gunter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Advanced glycation end products; Diabetic nephropathy; Erythropoietin; Neuropilin 1; P27 Kip1; Podocytes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; NEUROPILIN 1; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION;

ANIMALS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; GLYCOSYLATION END PRODUCTS, ADVANCED; MICE; NEUROPILIN-1; PODOCYTES; POLYETHYLENE GLYCOLS; RECEPTORS, ERYTHROPOIETIN; SERUM ALBUMIN, BOVINE;

EID: 77955099651     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319653     Document Type: Article

References (34)

1. Wolf G, Chen S, Ziyadeh FN: From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005; 54: 1626-1634.
2. White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G, de Cosmo S, Viberti G: Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002; 51: 3083-3089.
3. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99: 342-348.
4. Miyauchi M, Toyoda M, Kobayashi K, Abe M, Kobayashi T, Kato M, Yamamoto N, Kimura M, Umezono T, Suzuki D: Hypertrophy and loss of podocytes in diabetic nephropathy. Intern Med 2009; 48: 1615-1620.
5. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC: Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005; 16: 2941-2952.
6. Bohlender JM, Franke S, Stein G, Wolf G: Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005; 289:F645-F659.
7. D'Agati V, Yan SF, Ramasamy R, Schmidt AM: RAGE, glomerulosclerosis and proteinuria: roles in podocytes and endothelial cells. Trends Endocrinol Metab 2010; 21: 50-56.
8. Rüster C, Bondeva T, Franke S, Förster M, Wolf G: Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Nephrol Dial Transplant 2008; 23: 2179-2191.
9. Bondeva T, Rüster C, Franke S, Hammerschmid E, Klagsbrun M, Cohen CD, Wolf G: Advanced glycation end-products suppress neuropilin-1 expression in podocytes. Kidney Int 2009; 75: 605-616.
10. Bondeva T, Wolf G: Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity. Am J Nephrol 2009; 30: 336-345.
11. Wolf G, Müller N, Hunger-Battefeld W, Kloos C, Müller UA: Hemoglobin concentrations are closely linked to renal function in patients with type 1 or 2 diabetes mellitus. Kidney Blood Press Res 2008; 31: 313-321.
12. Mehdi U, Toto RD: Anemia, diabetes, and chronic kidney disease. Diabetes Care 2009; 32: 1320-1326.
13. Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, Levey AS, Sarnak MJ: Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol 2005; 16: 3403-3410.
14. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shanfinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003; 63: 1499-1507.
15. Goldman SA, Nedergaard M: Erythropoietin strikes a new cord. Nat Med 2002; 8: 785-787.
16. Fliser D, Bahlmann FH, de Groot K, Haller H: Mechanisms of disease: erythropoietin - an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 2006; 3: 563-572.
17. Schiffer M, Park JK, Tossidou I, Bartels J, Shushakova N, Menne J, Fliser D: Erythropoietin prevents diabetes-induced podocyte damage. Kidney Blood Press Res 2008; 31: 411-415.
18. Menne J, Park JK, Shushakova N, Mengel M, Meier M, Fliser D: The continuous erythropoietin receptor activator affects different pathways of diabetic renal injury. J Am Soc Nephrol 2007; 18: 2046-2053.
19. Mundel P, Reiser J, Zúñiga Mejía Borja A, Pavenstädt H, Davidson GR, Kriz W, Zeller R: Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258.
20. Shankland SJ, Pippin JW, Reiser J, Mundel P: Podocytes in culture: past, present, and future. Kidney Int 2007; 72: 26-36.
21. Busch M, Franke S, Wolf G, Brandstädt A, Ott U, Gerth J, Hunsicker LG, Stein G: The advanced glycation end product N(epsilon)- carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis 2006; 48: 571-579.
22. Wolf G, Schroeder R, Zahner G, Stahl RAK, Shankland SJ: High glucose-induced hypertrophy of mesangial cells requires p27 Kip1, an inhibitor of cyclin-dependent kinases. Am J Pathol 2001; 158: 1091-1100.
23. Echigoya MH, Obikane K, Nakashima T, Sasaki S: Glomerular localization of erythropoietin receptor mRNA and protein in neonatal and mature mouse kidney. Nephron Exp Nephrol 2005; 100:e21-e29.
24. Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, Kurihara H, Kawachi H, Shankland SJ, Fujita T, Nangaku M: Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007; 72: 455-463.
25. Thomas MC, Forbes JM, Cooper ME: Advanced glycation end products and diabetic nephropathy. Am J Ther 2005; 12: 562-572.
26. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, Bucciarelli LG, Rong LL, Moser B, Markowitz GS, Stein G, Bierhaus A, Liliensiek B, Arnold B, Nawroth PP, Stern DM, D'Agati V, Schmidt AM: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162: 1123-1137.
27. Juul SE, Yachnis AT, Christensen RD: Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998; 52: 235-249.
28. Morakkabati N, Gollnick F, Meyer R, Fandrey J, Jelkmann W: Erythropoietin induces Ca 2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol 1996; 24: 392-397.
29. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F, Tabira T, Sasaki R: Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993; 268: 11208-11216.
30. Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ: Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007; 72: 489-498.
31. Toba H, Sawai N, Morishita M, Murata S, Yoshida M, Nakashima K, Morita Y, Kobara M, Nakata T: Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 2009; 612: 106-114.
32. Bahlmann FH, Song R, Boehm SM, Mengel M, von Wasielewski R, Lindschau C, Kirsch T, de Groot K, Laudeley R, Niemczyk E, Güler F, Menne J, Haller H, Fliser D: Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012.
33. Bi B, Guo J, Marlier A, Lin SR, Cantley LG: Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol 2008; 295:F1017-F1022.
34. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.